Eli Lilly Expands Zepbound Offerings, Lowers Prices for Self-Pay Patients
INDIANAPOLIS, Feb. 25, 2025 – Eli Lilly and Company (NYSE: LLY) has introduced 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, priced at $499 through the new Zepbound Self Pay Journey Program. The company also reduced the cost of 2.5 mg and 5 mg vials.
Available exclusively via LillyDirect Self Pay Pharmacy Solutions, this initiative bypasses third-party entities to offer transparent pricing. The Obesity Action Coalition praised the move but emphasized the need for broader healthcare coverage.
Lilly lowered the 2.5 mg vial to $349 per month and 5 mg to $499, while the 7.5 mg ($599) and 10 mg ($699) vials now cost $499 if refilled within 45 days.
Lilly’s Patrik Jonsson reiterated the company’s commitment to making obesity treatment more affordable while advocating for improved insurance coverage.
Commenti
Posta un commento